期刊
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
卷 34, 期 7, 页码 531-537出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/jop.2017.0146
关键词
glaucoma; aqueous humor dynamics; EP2 receptor; intraocular pressure
资金
- Research to Prevent Blindness (University of Nebraska Medical Center)
- Research to Prevent Blindness (Case Western Reserve University)
- Santen Pharmaceutical Co., Ltd.
Purpose: To investigate the mechanism of the intraocular pressure (IOP)-lowering effect of a novel selective prostaglandin E2 receptor 2 (EP2) receptor agonist, omidenepag isopropyl (OMDI). Methods: The effect of OMDI on IOP and aqueous humor dynamics was evaluated in cynomolgus monkeys with unilateral laser-induced ocular hypertension. In a crossover manner, the hypertensive eye of each monkey was dosed once daily with 20L of either 0.002% OMDI or vehicle. On day 7 of dosing, IOP was measured by pneumatonometry, aqueous humor flow and outflow facility were evaluated by fluorophotometry, and uveoscleral outflow was calculated mathematically. Treatments were compared by paired t-tests. Results: OMDI at 0.002% significantly lowered IOP by 27%, 35%, and 44% at 0.5, 1.5, and 4h after the last dosing, respectively. There was no difference in aqueous humor flow between vehicle and OMDI treatments. When comparing OMDI to the vehicle treatment, outflow facility and uveoscleral outflow were significantly (P<0.05) increased by 71% and 176%, respectively. Conclusions: OMDI, a novel IOP-lowering compound, reduced IOP by increasing outflow facility and uveoscleral outflow in nonhuman primates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据